The chemotherapeutic Mitomycin C is widely used to treat BLCA, and here, we detect, in the BLCA specific analysis, a sensitizing interaction with mutations in TP53 (p = 9.9 × 10−5, CD = 2.8) that are highly prevalent in this cancer type. This evidence concerns the gene TP53 and bladder transitional cell carcinoma.